Neuronal deficiency of p38α-MAPK ameliorates symptoms and pathology of APP or Tau-transgenic Alzheimer's mouse models by Schnöder, Laura et al.
9628 |    The FASEB Journal. 2020;34:9628–9649.wileyonlinelibrary.com/journal/fsb2
Received: 6 November 2019 | Revised: 30 April 2020 | Accepted: 11 May 2020
DOI: 10.1096/fj.201902731RR  
R E S E A R C H  A R T I C L E
Neuronal deficiency of p38α-MAPK ameliorates symptoms and 
pathology of APP or Tau-transgenic Alzheimer’s mouse models
Laura Schnöder1,2 |   Gilles Gasparoni3 |   Karl Nordström3 |   Andrea Schottek1,2 |   
Inge Tomic1,2 |   Anne Christmann4 |   Karl H. Schäfer4 |   Michael D. Menger5 |   
Jörn Walter3 |   Klaus Fassbender1,2 |   Yang Liu1,2
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited and is not used for commercial purposes.
© 2020 The Authors. The FASEB Journal published by Wiley Periodicals LLC on behalf of Federation of American Societies for Experimental Biology
Abbreviations: AD, Alzheimer’s disease; adcy, adenylate cyclase; AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; APP, Alzheimer's 
amyloid precursor protein; APPtg, human APP-transgenic; APPwt, non-APP-transgenic; Aβ, amyloid β peptide; BACE1, β-secretase 1; BDNF, brain-derived 
neurotrophic factor; C99, C-terminal 99-aminoacid APP fragment; CCL-2, chemokine (C–C motif) ligand 2; Chi3l3, chitinase-like 3; ER, endoplasmic 
reticulum; ERK, like extracellular signal-related kinases; FA, formic acid; gapdh, glyceraldehyde 3-phosphate dehydrogenase; gnas, guanine nucleotide-
binding protein; GO, gene ontology; gria1, glutamate ionotropic receptor AMPA type subunit 1; grin2a, glutamate ionotropic receptor NMDA type subunit 
2A; Iba-1, ionized calcium-binding adapter molecule 1; IGF -1, insulin growth factor 1; IL-1β, interleukin 1β; iNOS, inducible nitric oxide synthase; JNK, 
C-Jun N-terminal kinase; LTD, long term depression; LTP, long term potentiation; Mrc1, mannose receptor, C type 1; Munc18-1, Munc18-1 protein 
mammalian homolog; p38α-MAPK, p38 mitogen-activated protein kinase type α; NeuN, neuronal nuclei; NMDAR, N-methyl-d-aspartate receptors; 
PSD-95, postsynaptic density protein 95; p-Tau, hyper-phosphorylated Tau; RAB, high-salt reassembly buffer; RIPA, radioimmunoprecipitation assay; RT, 
room temperature; sec, seconds; sigmar1, sigma non-opioid intracellular receptor1; slc8a1, solute carrier family 8 (sodium/calcium exchanger) member; 
SNAP-25, synaptosome-associated protein 25; Tautg, human Tau-transgenic; Tauwt, non-Tau-transgenic; TNF-α, tumor necrosis factor α.
1Department of Neurology, Saarland 
University, Homburg, Germany
2German Institute for Dementia Prevention 
(DIDP), Saarland University, Homburg, 
Germany
3Department of Genetics, Saarland 
University, Saarbrücken, Germany
4Working Group Enteric Nervous 
System, University of Applied Sciences, 
Zweibrücken, Germany
5Department of Experimental Surgery, 
Saarland University, Homburg, Germany
Correspondence
Yang Liu, Department of Neurology, 




Deutsche Forschungsgemeinschaft (DFG), 
Grant/Award Number: LI1725/2-1; German 
federal ministry of research and education, 
Grant/Award Number: 031L0101D; 
HOMFORexcell program
Abstract
Alzheimer's disease (AD) is the leading cause of dementia with very limited thera-
peutic options. Amyloid β (Aβ) and phosphorylated Tau (p-Tau) are key pathogenic 
molecules in AD. P38α-MAPK is specifically activated in AD lesion sites. However, 
its effects on AD pathogenesis, especially on p-Tau-associated brain pathology, 
and the underlying molecular mechanisms remain unclear. We mated human APP-
transgenic mice and human P301S Tau-transgenic mice with mapk14-floxed and 
neuron-specific Cre-knock-in mice. We observed that deletion of p38α-MAPK spe-
cifically in neurons improves the cognitive function of both 9-month-old APP and 
Tau-transgenic AD mice, which is associated with decreased Aβ and p-Tau load 
in the brain. We further used next-generation sequencing to analyze the gene tran-
scription in brains of p38α-MAPK deficient and wild-type APP-transgenic mice, 
which indicated that deletion of p38α-MAPK regulates the transcription of calcium 
homeostasis-related genes, especially downregulates the expression of grin2a, a 
gene encoding NMDAR subunit NR2A. Cell culture experiments further verified 
that deletion of p38α-MAPK inhibits NMDA-triggered calcium influx and neuronal 
apoptosis. Our systemic studies of AD pathogenic mechanisms using both APP- and 
Tau-transgenic mice suggested that deletion of neuronal p38α-MAPK attenuates 
AD-associated brain pathology and protects neurons in AD pathogenesis. This study 
supports p38α-MAPK as a novel target for AD therapy.
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1 |  INTRODUCTION
Alzheimer's disease (AD) is pathologically characterized by 
extracellular deposits of amyloid β peptide (Aβ) and intra-
cellular neurofibrillary tangles primarily composed of hyper 
phosphorylated Tau (p-Tau).1 Growing evidence shows that 
Aβ initiates AD pathogenesis: (a) Aβ aggregates directly 
injure synaptic junctions and neurons in the neocortex and 
limbic system,2 (b) aggregated Aβ triggers microglia-domi-
nated neurotoxic inflammatory activation,3 and (c) both Aβ 
and neuroinflammation induce phosphorylation of Tau,4,5 
and drive Tau pathology to expand along axonal projections 
to the entire neocortex.6,7 Therefore, the reduction of cerebral 
Aβ is desirable in AD therapy.
The β-secretase (BACE1) is a speed-limiting enzyme in 
Aβ generation from Alzheimer's amyloid precursor protein 
(APP).8 Many approaches to inhibit BACE1 have been at-
tempted; unfortunately, these studies have not yet led to effica-
cious therapy for AD patients.9 In contrast, the intervention of 
BACE1 potentially brought severe side effects and even safety 
problems as BACE1 has various physiological substrates.10 We 
recently observed that reduction of p38α-MAPK, a stress-as-
sociated kinase which is highly activated at AD lesion sites in 
early disease stages,11,12 facilitated lysosomal degradation of 
BACE1 in neurons.13 We argue that inhibition of p38α-MAPK 
might be an alternative method to block BACE1-mediated Aβ 
production. Moreover, deficiency of p38α-MAPK reduces 
Aβ-triggered inflammatory activation in cultured microglia.14 
p38-MAPK has been shown to phosphorylate recombinant 
Tau protein,15 and has been observed to bind p-Tau in the AD 
brain.12,16 There is also evidence that p38-MAPK might me-
diate Aβ-induced synaptic impairment.17,18 An exploratory 
clinical study on p38α-MAPK inhibitor did show a promis-
ing result that p38α-MAPK inhibition might improve episodic 
memory and impact amyloid deposits in AD patients.19 Thus, 
it is worthwhile to extensively investigate the pathophysiolog-
ical role of p38α-MAPK in AD.
Administration of p38α-MAPK inhibitor in both APP- 
and Tau-transgenic AD mice suppresses inflammatory 
activation and attenuates neuronal deficits in the brain.20-
22 However, pharmacological experiments are not able to 
distinguish the effect from neuronal and microglial p38α-
MAPK. Deletion of p38α-MAPK specifically in neurons 
reduced cerebral Aβ and BACE1 proteins in 5×FAD mice,23 
which corroborates our previous finding.13 However, this 
study did not further decode the underlying mechanisms 
mediating neuronal protection. Moreover, most preclinical 
studies on p38α-MAPK have used APP-transgenic mice 
as AD models and neglected the effects of p38α-MAPK 
on p-Tau-associated pathology, which prevent comprehen-
sively understanding the pathogenic role of p38α-MAPK 
in AD.
To address these questions, we deleted p38α-MAPK 
in neurons of both APP- and Tau-transgenic mice and ob-
served that deletion of neuronal p38α-MAPK attenuated 
cognitive dysfunctions in association with decreased loads 
of Aβ and p-Tau, and inhibited inflammatory activation in 
the brain. We further compared the transcriptome in brains 
from neuronal p38α-MAPK-deficient and wild-type APP-
transgenic mice, and showed that deletion of p38α-MAPK 
might regulate neuronal calcium homeostasis and protect 
neurons in AD.
2 |  MATERIALS AND METHODS
2.1 | Animal models and cross-breeding
Our APP-transgenic (APPtg) mice over-expressing 
human mutated APP (KM670/671NL) and presenilin-1 
(L166P) under Thy-1 promoters24 were kindly provided 
by M. Jucker, Hertie Institute for Clinical Brain Research, 
Tübingen; p38fl/fl mice carrying loxP site-flanked mapk14 
gene were provided by K. Otsu, Osaka University;25 and 
K. Nave, Max-Planck-Institute for Medicine, Göttingen, 
kindly provided Nex-Cre mice, expressing Cre recom-
binase from the endogenous locus of nex gene.26 APPtg, 
p38fl/fl, and Nex-Cre mice, all on a C57BL6 genetic back-
ground, had been cross-bred in our previous study to build 
AD animal models with (APPtgp38αfl/flCre+/−) and with-
out (APPtgp38αfl/flCre−/−) deletion of p38α-MAPK in 
neurons.13 In order to investigate physiological function 
of p38α-MAPK in neurons, we also examined non-APP-
transgenic (APPwt) mice with (APPwtp38αfl/flCre+/−) and 
without (APPwtp38αfl/flCre−/−) deletion of neuronal p38α-
MAPK. To evaluate the effect of neuronal p38α-MAPK 
on p-Tau-induced phenotype, we cross-bred p38fl/fl and 
Nex-Cre mice, with P301S Tau-transgenic (Tautg) mice 
(imported from the Jackson Laboratory, Bar Harbor, MA, 
USA; Stock: #008169), which over-express the human Tau 
mutant (P301S) under the direction of mouse prion protein 
promoter.27 For this study, 9-month-old male and female 
mice were used. All animal experiments were performed in 
accordance with relevant national rules and authorized by 
the local research ethical committee (permission numbers: 
40/2014 and 49/2016).
K E Y W O R D S
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2.2 | Morris water maze
The Morris water maze test, consisting of a 6-day training 
phase and a 1-day probe trial, was used to assess the cogni-
tive function of APPtg or Tautg mice and their APPwt litter-
mates, as previously described.28
2.3 | Tissue collection for histological and 
biochemical analysis
Animals were euthanized by inhalation of isoflurane. The 
brain was removed and divided. The left hemisphere was 
immediately fixed in 4% paraformaldehyde (Sigma-Aldrich 
GmbH, Taufkirchen, Germany) and embedded in paraffin. 
A 0.5-μm-thick piece of tissue was sagittal cut from the 
right hemisphere. The cortex and hippocampus were sepa-
rated and homogenized in TRIzol (Thermo Fisher Scientific, 
Darmstadt, Germany) for RNA isolation. The remainder of 
the right hemisphere was snap-frozen in liquid nitrogen and 
stored at −80°C until biochemical analysis. To evaluate the 
activity of p38-MAPK, we also collected heart, left lobe of 
liver, and skeletal muscles of quadriceps.
2.4 | Western blot analysis
Frozen mouse brains were homogenized on ice in radioim-
munoprecipitation assay buffer (RIPA buffer; 50  mM Tris 
[pH 8.0], 150 mM NaCl, 0.1% SDS, 0.5% sodiumdeoxy-cho-
late, 1% NP-40, and 5 mM EDTA) supplemented with pro-
tease inhibitor cocktail (Roche Applied Science, Mannheim, 
Germany) and phosphatase inhibitors (50 nM okadaic acid, 
5  mM sodium pyrophosphate, and 50  mM NaF; Sigma-
Aldrich). To quantify p-Tau and total Tau (t-Tau) proteins, 
the brain tissue was sequentially homogenized in ice-cold 
high-salt reassembly buffer (RAB; 0.1  M MES, 1  mM 
EGTA, 0.5  mM MgSO4, 0.75  M NaCl, 20  mM NaF, and 
1  mM PMSF), RIPA buffer, and 70% formic acid (FA).28 
Human Aβ, Tau, and other brain proteins were quantified 
with previously established Western blot13,28 using antibod-
ies listed in Table 1.
2.5 | Golgi - Cox staining
Serial 100-μm-thick sagittal sections were cut from mouse 
brains using a vibratome (VT1000S, Leica Mikrosysteme 
Vertrieb GmbH, Wetzlar, Germany) and stained with Rapid 
Golgi Staining Kit (FD NeuroTechnologies, Columbia, 
MA, USA). Images of neurons at hippocampal CA1 and 
CA3 and at cortex (layer II/III) were obtained on a Zeiss 
AxioImager.Z2 microscope with a 63× oil-objective and a 
z-stack distance of 0.5 μm (Zeiss Microscopy, Göttingen, 
Germany). The number of spines per micrometer of den-
dritic length was determined in second- or third-order 
dendritic branches of apical dendrites. At minimum, three 
serial sections per animals with 500  μm of interval were 
analyzed. Moreover, the morphology of dendritic spines 
were analyzed and spines were grouped into mature (mush-
room), immature (thin and stubby), and filopodia-like 
spines according to the published classification.29 The ex-
perimenter was blinded to the genotypes of mice during the 
entire experiment.
T A B L E  1  List of antibodies used for quantitative Western blot
Antibodies Supplier Species Type Reference
p38-MAPK Cell Signaling Technology Rabbit Polyclonal Catalog no. 9212
phosphorylated p38-MAPK Cell Signaling Technology Rabbit Polyclonal Catalog no. 9211
PSD-95 Cell Signaling Technology Rabbit Polyclonal Catalog no. 2507
SNAP-25 Cell Signaling Technology Rabbit Polyclonal Catalog no. 3926
Munc18-1 Cell Signaling Technology Rabbit Polyclonal Catalog no. 13414
synaptophysin Abcam Mouse Monoclonal Clone SY38
Aβ Merck Chemicals GmbH Mouse Monoclonal Clone W0-2
Tau Thermo Fisher Scientific Mouse Monoclonal Clone HT7
Phosphorylated Tau Thermo Fisher Scientific Mouse Monoclonal Clone AT8
Grin2a Cell Signaling Technology Rabbit Polyclonal Catalog no. 4205
β-actin Cell Signaling Technology Rabbit Monoclonal Clone 13E5
α-tubulin Abcam Mouse Monoclonal Clone DM1A
LC3B Cell Signaling Technology Rabbit monoclonal Clone D11
Cleaved Caspase-3 Cell Signaling Technology Rabbit Monoclonal Clone 5A1E
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2.6 | Immunohistological analysis
Serial 50-μm-thick sagittal sections were cut from the paraf-
fin-embedded hemisphere. Human Aβ in APPtg mouse brains 
was stained with mouse anti-human Aβ antibody (clone 
6F/3D; Dako Deutschland GmbH, Hamburg, Germany) and 
microglia labeled with rabbit anti-ionized calcium-binding 
adapter molecule (Iba)-1 antibody (Wako Chemicals, Neuss, 
Germany). For each animal we labeled four sections with an 
interval of 10 layers between neighbouring sagittal sections. 
In the whole hippocampus and cortex, volumes of Aβ were 
estimated with the Cavalieri method, and Iba-1-positive cells 
were counted with Optical Fractionator as described previ-
ously30 on a Zeiss AxioImager.Z2 microscope equipped with 
a Stereo Investigator system (MBF Bioscience, Williston, 
VT, USA).
To evaluate Tau pathology in Tautg mice, four serial 
50-μm-thick sections were chosen as for Aβ analysis. Brain 
tissues were stained according to the published protocols31 
with a mouse monoclonal antibody against human phos-
pho-Tau (Ser202, Thr205) (clone: AT8; Thermo Fisher 
Scientific) or with thioflavine S (Sigma-Aldrich GmbH). 
Thioflavine S staining was used to identify neurofibrillary 
tangles. Because of low numbers of p-Tau or thioflavine S 
staining-positive cells in the cortex and hippocampus, we did 
not use stereological analysis, but counted labeled cells in the 
whole brain region. Data were recorded as the number of la-
beled cells divided by the full area (in square millimeters) of 
interest.
To evaluate the efficiency and specificity of Nex-Cre-
mediated deletion of p38α-MAPK, we co-stained brain sec-
tions from 9-month-old APPtgp38αfl/flCre+/− and APPtgp38αfl/
flCre−/− mice with antibodies against NeuN (clone: D4G40; 
Cell Signaling Technology, Frankfurt am Main, Germany), 
and p38α-MAPK (clone: 9F12; Novus Biologicals, 
Wiesbaden, Germany), and then, with Alexa Fluor 488 and 
CY3-conjugated secondary antibodies, respectively. Nuclei 
were counterstained with DAPI. We randomly chose cortical 
regions under 40× objective. In the channels for Alexa Fluor 
488 and DAPI fluorescence, we first counted NeuN-positive 
and negative cells with clear nuclear staining. Thereafter, 
we imaged sections in the channel for CY3 to count p38α-
MAPK-staining positive cells. More than 800 NeuN-positive 
cells and >400 NeuN-negative cells were counted and the 
percentages of p38α-MAPK-positive cells within these two 
groups of cells were calculated.
2.7 | Quantitative PCR for analysis of gene 
transcripts
Total RNA was isolated from mouse brains and reverse 
transcribed. Gene transcripts of pro-and anti-inflammatory 
markers were quantified with our established protocol30 
using Taqman gene expression assays of mouse tnf-α, il-1β, 
chemokine (C–C motif) ligand 2 (ccl-2), inducible nitric oxide 
synthase (inos), il-10, arginase 1 (arg1), mannose receptor C 
type 1 (mrc1), chitinase-like 3 (chi3l3), brain-derived neuro-
trophic factor (bdnf), insulin growth factor (igf)-1, and glyc-
eraldehyde 3-phosphate dehydrogenase (gapdh) (Thermo 
Fisher Scientific). After next generation sequencing analy-
sis, the transcription of following target genes encoding: 
adenylate cyclase 3 and 7 (adcy3, adcy7), ATPase plasma 
membrane Ca2+ transporting 4 (atp2b4), guanine nucleo-
tide-binding protein (gnas), grin2a, 5-hydroxytryptamine 
receptor 7 (htr7), solute carrier family 8 (sodium/calcium ex-
changer), member 1 (slc8a1), sphingosine kinase 1 (sphk1), 
transmembrane protein 63C (tmem63c), phosphoinositide-
specific phospholipase C (plch1), and nuclear factor of ac-
tivated T cells 2 (nfatc2), was determined using SYBR green 
binding technique with primers shown in Table 2. For nfatc2 
detection, two different sets of primers for transcript variants 
were used.
2.8 | RNA purification for next 
generation sequencing
RNA from 9-month-old p38α-MAPK-deficient and wild-
type APPtg littermate mice was purified using the RNeasy 
Plus Mini Kit (Qiagen GmbH, Hilden, Germany) accord-
ing to the manufacturer's instructions. The concentra-
tion and integrity of RNA were tested using the Agilent 
2100 Bioanalyzer (Santa Clara, CA, USA). RNA samples 
with RNA integrity number > 6 were used to build RNA-
sequencing libraries.
2.9 | Preparation of RNA-
sequencing library
The RNA-seq library was built with 600 ng total RNA using 
the NEBNext Poly(A) mRNA Magnetic Isolation Module 
(Ipswich), NEBNext Ultra Directional RNA Library Prep 
Kit for Illumina (E7420) and NEBNext Multiplex Oligos 
for Illumina (Index-Set2) (New England Biolabs GmbH, 
Frankfurt am Main, Germany). Briefly, mRNA was en-
riched using AMPure XP Beads (Beckman Coulter GmbH, 
Krefeld, Germany), fragmented using enzymes, and then, 
reverse transcribed into cDNA with random primers. 
Thereafter, double stranded cDNA was adaptor-ligated and 
amplified by PCR for 10 cycles. The quality of libraries 
was evaluated using the High Sensitivity DNA Chip in the 
Agilent 2001 Bioanalyzer and quantified by qPCR with the 
PerfeCTa NGS quantification kit from QuantaBio (Beverly, 
MA, USA).
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2.10 | Illumina Sequencing and 
Sequence alignment
The libraries were sequenced on the Illumina Hiseq2500 
platform (San Diego, CA, USA) with 101-bp single-end 
reads. After QC with FastQC Version 0.11.2 (http://www.
bioin forma tics.bbsrc.ac.uk/proje cts/fastq c/), reads were 
adaptor-trimmed (Q < 20) with Cutadapt (Version 1.4.132) 
with a wrapper Trim Galore! (Version 0.3.3) (https://www.
bioin forma tics.babra ham.ac.uk/proje cts/trim_galor e/). 
Reads were aligned with the grape-nf pipeline (https://github.
com/guigo lab/grape -nf) wrapping STAR (Version 2.4.0j33) 
and RSEM (Version 1.2.2134). Read counts were imported 
into R with tximport (Version 1.6.035). Differentially ex-
pressed genes were identified with edgeR (Version 3.20.936). 
Transcripts with an absolute log2-fold change greater than 2 
and a FDR value below 0.01 were considered differentially 
expressed.
2.11 | Gene ontology (GO) and 
pathway analysis
The biological function of individual genes was identified 
by GO analysis (http://cbl-goril la.cs.techn ion.ac.il/). KEGG 
pathways with high gene transcript clustering were processed 
and downloaded using the online software Pathview.37-39
2.12 | Culture of primary neurons
Cortex was collected from embryos (E14  ±  0.5) from the 
breeding of APPtgp38fl/flNex-Cre+/− (or APPwtp38fl/flNex-
Cre+/−) male and APPwtp38fl/flNex-Cre−/− female mice. After 
digestion with trypsin for 15 minutes at 37°C, the single cell 
suspension (2×105 cells) was seeded on a poly-l-lysine-
coated coverslip with 15 mm of diameter. Primary neurons 
were cultured for 14 ± 2 days at 37°C and 10% CO2 in neu-
robasal medium supplemented with 2% B27, 0.25% l-Glu-
tamine, and 0.1% Glutamax (all reagents were bought from 
Thermo Fisher Scientific).
2.13 | Calcium imaging of primary neurons
The functional analysis of altered calcium homeostasis was 
evaluated by calcium imaging. We incubated the neurons 
with 5 μM Fluo-4 (Thermo Fisher Scientific) for 30 minutes 
at RT. After washing, we aligned the coverslip in a perfusion 
chamber RC-20 (Warner Instruments, Hamden, CT, USA) 
and applied a constant perfusion (0.5  mL/min) with imag-
ing buffer (148 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM 
MgCl2, 10 mM Glucose, 10 mM HEPES [pH 7.38]). Calcium 
images were taken with an inverse Olympus microscope (IX-
70; Olympus Deutschland GmbH, Hamburg, Germany), 
equipped with a 20× objective (Olympus) and a CCD cam-
era (Orca-II-ER; Hamamatsu Photonics Deutschland GmbH, 
Herrsching am Ammersee, Germany). The basal activity of 
neurons was detected for 90 seconds. Then, the neurons of 
both genotypes were stimulated with either 100  μM l-glu-
tamate or 50 μM NMDA (both from Sigma-Aldrich) in im-
aging buffer. When the calcium response reached a plateau, 
500 μM l-glutamate (at 400 seconds) or 10 mM NMDA (at 
300 seconds) was further administered to neurons. As a con-
trol, 75 mM KCl was used to stimulate neurons. Images were 
processed and analyzed with the software CellObserver Z1 
and Axiovision (Zeiss Microscopy, Göttingen, Germany). 
Region of interests were set around the fluorescent neuronal 
cell bodies. The ratio F/F0 was calculated (F: fluorescent in-















T A B L E  2  List of primer sequences 
used for SYBR green based quantitative 
RT-PCR
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at the time point 0). Calcium influx (ΔCa2+) = (F−F0)/F0. 
Four independent experiments were performed for each stim-
ulator. The mean value of ΔCa2+ from all analyzed cells on 
the same coverslip was calculated for each animal.
To evaluate intracellular calcium buffering capacity, we 
stimulated p38α-MAPK-deficient and wild-type neurons 
with 100  µM l-glutamate for 20  seconds after 60  seconds 
of baseline acquisition. Thereafter, a constant perfusion 
(0.5 mL/min) with imaging buffer was applied to the cham-
ber to wash out l-glutamate for around 180  seconds (until 
the fluorescence intensity returned to the baseline level). The 
time during which the intensity of Fluo-4 fluorescence went 
back to the baseline after wash-out was calculated as decay 
time (see Figure 6F).
To investigate the effects of p38α-MAPK deletion on cal-
cium influx after blocking NMDAR, we continued to per-
fuse p38α-MAPK-deficient and wild-type neurons from the 
wash-out experiment (described above) constantly with im-
aging buffer containing 100 µM NMDAR antagonist, 2-APV 
(Tocris Bioscience, Wiesbaden-Nordenstadt, Germany; Cat. 
No.: 0106) at 0.5 mL/min for 300 seconds. Thereafter, neu-
rons were again stimulated with 100  µM l-glutamate for 
20  seconds in presence of 100  µM 2-APV. After a further 
180-sec treatment with 100 µM 2-APV, neurons were washed 
with pure imaging buffer (see Figure 6F).
In all calcium imaging experiments, the experimenter was 
blinded to the genotypes of cells.
2.14 | Apoptosis assay of p38α-MAPK-
deficient and wild-type primary neurons
To evaluate the effects of p38α-MAPK deficiency on cal-
cium influx-induced neuronal death, we treated cultured 
p38α-MAPK-deficient and wild-type neurons with 100 µM 
l-glutamate or 50 µM NMDA for 16 hours. Thereafter, neu-
rons were harvested and lysed in RIPA buffer. Quantitative 
Western blot was used to detect caspase-3 activity in the 
cell lysate with antibodies specifically against cleaved cas-
pase-3 (Clone 5A1E; Cell Signaling Technology). This an-
tibody detects cleaved (active) caspase-3 without showing 
pro-caspase-3.
2.15 | Statistics
Data were presented as mean ± SEM. For multiple compari-
sons, one-way or two-way ANOVA followed by Bonferroni, 
Tukey, or Dunnett T3 post hoc test (dependent on the result 
of Levene's test to determine the equality of variances) was 
used. Two independent-samples Students t test was used to 
compare means for two groups of cases. All statistical analy-
ses were performed with SPSS version 19.0 for Windows 
(IBM, New York, NY, USA). Statistical significance was set 
at P < .05.
3 |  RESULTS
3.1 | Determination of lesion sites-associated 
activation of p38-MAPK in APP-transgenic 
mice and establishment of neuronal p38α-
MAPK-deficient AD mouse models
Based on previous reports showing that p38-MAPK is acti-
vated in association with AD pathological changes,6,11,12,40 
we hypothesized that phosphorylation of p38-MAPK would 
be greater in APPtg mice compared to non-APP-transgenic 
(APPwt) animals. We measured p38-MAPK activities in 
brain, heart, muscles, and liver of 9-month-old APPtg and 
APPwt littermates. The results showed that phosphorylation 
of p38-MAPK was increased in the brain of the APPtg mice, 
compared to the APPwt littermates, but not in the other organs 
tested (Figure 1A,B; t test, P = .025), confirming that p38-
MAPK is activated in association with AD lesions.
To verify the deletion of p38α-MAPK in the brain, we 
measured the cerebral protein levels of p38-MAPK in 
9-month-old APPtgp38αfl/flCre+/− and APPtgp38αfl/flCre−/− 
littermate mice and found the levels of p38-MAPK to be 75% 
lower in Cre-positive mice compared to Cre-negative litter-
mates (Figure 1C,D; p38-MAPK/α-tubulin: 0.245 ± 0.036 vs 
1.005 ± 0.162, respectively; t test, P = .003).
We then co-stained p38α-MAPK and NeuN, a neuronal 
marker, in brains of 9-month-old APPtgp38αfl/flCre+/− and 
APPtgp38αfl/flCre−/− littermates. In the cortex of APPtgp38αfl/
flCre−/− mice, p38α-MAPK protein was stained and shown 
in puncta around the nucleus in 48.67  ±  6.95% NeuN anti-
body-stained cells (Figure  1E), whereas, only 12.81  ±  3.86% 
NeuN-positive cells in APPtgp38αfl/flCre+/− mice showed p38α-
MAPK signals (Figure 1F; t test, P < .001). In NeuN-negative 
brain cells, the staining of p38α-MAPK was not different be-
tween these two groups of AD mice (Figure 1F; 21.39 ± 4.85% 
vs 19.59  ±  4.06%, in APPtgp38αfl/flCre+/− and APPtgp38αfl/
flCre−/− mice, respectively; t test, P > .05). The cellular specific-
ity of Cre-mediated p38α-MAPK deletion in neurons of APPtg 
mice corroborates our previous observation.13
Interestingly, in the additional experiments, we ob-
served that deletion of p38α-MAPK was able to further 
inhibit phosphorylation of the rest of p38-MAPK protein 
in p38α-MAPK-deficient APPtg mouse brain but not in 
p38α-MAPK-deficient APPwt mice (Figure  1G,H; one-way 
ANOVA, P < .05).
In our study, we produced a total of 361 new-born mice 
from the following two breeding pairs: (a) APPtgp38αfl/
flCre+/− [male] and APPwtp38αfl/flCre−/− [female], 
and (b) APPtgp38αfl/flCre−/− [male] and APPwtp38αfl/
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flCre+/− [female]. The genotypes (percentages) of the new-
born mice were APPwtp38αfl/flCre−/− (19.11%), APPwtp38αfl/
flCre+/− (30.75%), APPtgp38αfl/flCre−/− (22.44%), and 
APPtgp38αfl/flCre+/− (27.70%), as shown in Table 3 (χ2 test 
between different genotypes, P = .984). Mice with deletion 
of p38α-MAPK appeared to be generally healthy, fertile, and 
behaviorally normal, demonstrating that deletion of neuronal 
p38α-MAPK is not toxic to the survival of mice.
F I G U R E  1  p38-MAPK is activated in APP-transgenic mouse brain and is efficiently deleted in neurons of APPtgp38fl/flCre+/− mice. The 
homogenates of brain, heart, muscle, and liver derived from 9-month-old APP-transgenic (APPtg) and wild-type (APPwt) littermates were analyzed 
for both phosphorylated (p-p38) and total (t-p38) p38-MAPK with Western blot (A and B, t test, n ≥ 4 per group). Western blot was also used to 
detect cerebral t-p38 in 9-month-old APPtgp38fl/flCre+/− (p38α-MAPK-ko) and APPtgp38fl/flCre−/− (p38α-MAPK-wt) littermate mice (C and D, 
t test, n = 5 per group). Brain sections of these mice were co-stained with fluorophore-conjugated antibodies against p38α-MAPK and NeuN in 
the cortex (E). In p38α-MAPK-wt mice, p38α-MAPK protein was shown in red puncta around the NeuN-staining nuclei in green (indicated with 
arrows), whereas, rare p38α-MAPK was stained in NeuN staining-positive neurons in p38α-MAPK-ko mice. In NeuN staining-negative cells, 
p38α-MAPK was stained in both p38α-MAPK-wt and ko mice (E, indicated with arrow heads). Nuclei were stained with DAPI in blue. The 
percentages of p38α-MAPK-stained cells in both NeuN-positive and negative cells were calculated and compared in p38α-MAPK-wt and ko APPtg 
mice (F, t test, n = 11 per group). The homogenates of brain derived from 9-month-old APPwt and APPtg littermates with and without deletion of 
p38α-MAPK were further analyzed for phosphorylation of p38-MAPK with quantitative Western blot. In this experiment, the loading protein for 
each lane was adapted to have similar amount of t-p38 (G and H, One-Way ANOVA followed by Bonferroni post hoc test, n ≥ 4 per group)
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3.2 | Deletion of neuronal p38α-MAPK 
attenuates cognitive deficits and synaptic 
impairments in APP-transgenic mice
In order to test the pathogenic effects of neuronal p38α-
MAPK on AD, we used the Morris water maze test to exam-
ine the cognitive function of 9-month-old APPtg and APPwt 
littermate mice with and without deletion of p38α-MAPK 
in neurons. As shown in Figure 2A-C, the swimming time 
and distance to reach the platform for all tested mice signifi-
cantly decreased when the training time increased (two-way 
ANOVA, P < .05); however, the swimming velocity did not 
differ between various groups of mice or for the same mice 
on different training dates (two-way ANOVA, P > .05).
We compared different genotypes of mice with respect 
to their behavior during the acquisition phase of the water 
maze test. APPwt littermate mice with or without defi-
ciency of p38α-MAPK in neurons (APPwtp38αfl/flCre+/− and 
APPwtp38αfl/flCre−/−) showed no significant differences in 
either swimming time or swimming distance before climbing 
onto the escape platform (Figure  2A,B; two-way ANOVA, 
P > .05). Compared to APPwtp38αfl/flCre+/− or APPwtp38αfl/
flCre−/− littermates, 9-month-old APPtg mice with wild-type 
p38α-MAPK expression in neurons (APPtgp38αfl/flCre−/−) 
spent significantly more time (Figure 2A; two-way ANOVA, 
P < .05) and traveled longer distances (Figure 2B; two-way 
ANOVA, P < .05) in the water maze before reaching the es-
cape platform. Interestingly, APPtgp38αfl/flCre+/− mice with 
the ablation of p38α-MAPK specifically in neurons per-
formed significantly better than their APPtgp38αfl/flCre−/− 
littermates in searching for and finding the platform after 
3 days of training (Figure 2A,B; two-way ANOVA followed 
by post hoc test showing APPtgp38αfl/flCre−/− vs APPtgp38αfl/
flCre+/− mice: P < .05).
Twenty-four hours after the end of the training phase, the 
escape platform was removed and a 5-minute probe trial was 
performed to test the memory of the mice. We evaluated three 
parameters: duration of time the mouse needed to find the 
original platform region, total number of times the mouse 
crossed the original platform region, and the total time the 
mouse spent in the original platform region. Compared to 
APPwtp38αfl/flCre+/− and APPwtp38αfl/flCre−/− littermates, 
APPtgp38αfl/flCre−/− mice took significantly longer time for 
their first visit to the region where the platform had been 
located, crossed the platform region with significantly less 
frequency, and spent significantly less time in the platform 
region during the total 5-minute probe trial (Figure  2D-
F; one-way ANOVA followed by post hoc test, P  <  .01). 
Interestingly, when compared to APPtgp38αfl/flCre−/− mice, 
APPtgp38αfl/flCre+/− mice were able to reach the original plat-
form region in significantly less time and crossed the region 
more frequently (Figure 2D,E; one-way ANOVA followed by 
post hoc test, P = .03 and 0.05, respectively). We observed no 
significant differences between the two APPwt control groups 
(APPwtp38αfl/flCre+/− and APPwtp38αfl/flCre−/− littermate 
mice) in any of the three parameters analyzed in the probe 
trial (Figure 2D-F; one-way ANOVA followed by post hoc 
test, P > .05).
We also used Western blot analysis to quantify the lev-
els of four synaptic-structure proteins: Munc18-1, synapto-
physin, SNAP-25, and PSD-95 in the brain homogenate of 
9-month-old APPtg and APPwt littermate mice. As shown 
in Figure 2 (panels G, H and J), protein levels of Munc18-1 
and synaptophysin in APPtgp38αfl/flCre−/− mice were sig-
nificantly lower than levels of these proteins derived from 
APPwtp38αfl/flCre+/− and APPwtp38αfl/flCre−/− littermate 
mice (one-way ANOVA followed by post hoc test, P < .05). 
Interestingly, the reduction in Munc18-1 and synaptophysin 
proteins due to APP-transgenic expression was rescued by 
the deletion of p38α-MAPK in neurons (one-way ANOVA 
followed by post-hoc test, P  <  .05). SNAP-25 protein lev-
els were significantly higher in brains from APPtgp38αfl/
flCre+/− mice than in brains from APPtgp38αfl/flCre−/− con-
trol mice (Figure 2G,I; one-way ANOVA followed by post 
hoc test, P < .05). Comparison of APPwtp38αfl/flCre+/− and 
APPwtp38αfl/flCre−/− littermate mice showed no significant 
differences in protein levels of these four tested synaptic pro-
teins (Figure 2G-K; one-way ANOVA followed by post hoc 
test, P > .05).
To further clarify whether deletion of neuronal p38α-MAPK 
protected synaptic integrity in APPtg mice, we evaluated the 
spine density and analyzed the morphology of spines of neu-
rons in dendritic branches of apical dendrites in hippocampal 
CA1 and CA3 areas, and in the cortex layer II/III. Consistent 
with the Western blot results, Golgi staining revealed that 
the spine density of neurons in all three tested brain regions 









Male 34 (33.8) 53 (54.4) 41 (39.7) 49 (49.0) 177 (177.0)
Female 35 (35.2) 58 (56.6) 40 (41.3) 51 (51.0) 184 (184.0)
Total 69 (69.0) 111 (111.0) 81 (81.0) 100 (100.0) 361 (361.0)
Note: Values in brackets indicate the expected counts from χ2 test.
χ2 = 0.156, F = 3 and P = .984.
T A B L E  3  Genotype distribution of 
newborns from the following two breeding 
pairs: (i) apptgp38αfl/flCre+/− [male] and 
appwtp38αfl/flCre−/− [female]; and (ii) 
apptgp38αfl/flCre−/− [male] and appwtp38αfl/
flCre+/− [female]
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APPtgp38αfl/flCre−/− littermates (Figure S1A,B; t test, P < .05). 
Moreover, dendritic spines were grouped into mature, imma-
ture and filopodia-like spines based on their morphologies.29 
Deficiency of p38α-MAPK appeared to preserve more mature 
(mushroom-shaped) spines than the spines of other types of 
morphology (Figure S1C-G; t test, P < .05).
3.3 | Deletion of neuronal p38α-
MAPK reduces cerebral Aβ burden and 
neuroinflammation in APP-transgenic mice
After observing that deletion of p38α-MAPK improved 
the cognitive performance in APPtg mice but not in APPwt 
F I G U R E  2  Deletion of p38α-MAPK in neurons improves cognitive function and attenuates synaptic impairments in APP-transgenic mice. 
During the training phase of the water maze test, 9-month-old APP-transgenic (tg) mice spent more time and traveled longer distances to reach 
the escape platform than did their non-APP-transgenic (APPwt) littermates. Deletion of p38α-MAPK in neurons (p38α ko) significantly reduced 
the traveling time and distance of APPtg, but not of APPwt mice after 3 days of training (A, B; two-way ANOVA from day 3 to day 6 followed 
by Bonferroni post hoc test, * P < .05, ** P < .01, *** P < .001; n ≥ 13 per group). However, deficiency of neuronal p38α-MAPK affected the 
swimming speed neither of APPtg and APPwt mice, nor for each mouse at different training time points (C; two-way ANOVA, P > .05; n ≥ 13 per 
group). In the probe trial, APPtg mice spent significantly longer in the first visit to the region where the platform was previously located, crossed 
the platform region with significantly less frequency and spent significantly less time in the platform region during the total 5-min experiment than 
APPwt mice; deletion of p38α-MAPK in neurons partially recovered these APP expression-induced cognitive impairments (D-F; one-way ANOVA 
followed by Bonferroni post hoc test, *P < .05, **P < .01, ***P < .001; n ≥ 13 per group). Western blotting was used to detect the amount of 
synaptic structure proteins, Munc18-1, SNAP25, synaptophysin, and PSD-95 in the brain homogenate of 9-month-old APPtg and APPwt mice  
(G-K). Deficiency in neuronal p38α-MAPK was associated with higher levels of Munc18-1, SNAP25, and synaptophysin in the APPtg mouse, but 
not in the APPwt mouse (t test; n ≥ 11 per group)
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littermates, we analyzed Aβ pathology in the AD mice, as 
Aβ is the key molecule leading to neurodegeneration in AD.2 
We used the stereological Cavalieri method to measure Aβ 
volume, adjusted relative to the volume of analyzed tis-
sues, in 9-month-old APPtgp38αfl/flCre−/− and APPtgp38αfl/
flCre+/− mice. The volume of immunoreactive Aβ load in 
the APPtgp38αfl/flCre−/− mice (1.364%  ±  0.140% in the 
hippocampus and 1.344%  ±  0.096% in the cortex) was 
significantly higher than in the APPtgp38αfl/flCre+/− mice 
(0.876% ± 0.086% in the hippocampus and 0.847% ± 0.079% 
in the cortex; Figure 3A,B; t test, P = .008 and 0.001, respec-
tively), suggesting that deletion of p38α-MAPK in neurons 
reduces the cerebral Aβ burden.
Western blot analysis using human Aβ-specific anti-
body was performed to determine the levels of Aβ mono-
mer, dimers and trimers and of C99 in the homogenate 
of cortex and hippocampus derived from 9-month-old 
APPtgp38αfl/flCre+/− and APPtgp38αfl/flCre−/− littermate 
mice. As shown in Figure 3C-E, deletion of p38α-MAPK 
in neurons reduced all four detected peptides by 35% when 
F I G U R E  3  Deletion of p38α-MAPK in neurons reduces cerebral Aβ in APP-transgenic mice. Nine-month-old APP-transgenic (tg) littermate 
mice with (ko) and without (wt) deletion of neuronal p38α-MAPK were analyzed for cerebral Aβ load after immunohistochemical staining of 
human Aβ (A). The Aβ volume was estimated with Cavalieri method and adjusted by the relevant brain volume. Deletion of p38α-MAPK in 
neurons significantly reduced the cerebral Aβ volume (B; t test; n ≥ 10 per group). The cerebral Aβ in APPtg mice was also evaluated by detecting 
Aβ in the brain homogenate with quantitative Western blot (C). Both, normalization of Aβ against β-actin (D) and against APP (E), show reduced 
Aβ load after deletion of p38α-MAPK in neurons (C-E; t test; n ≥ 4 per group). The protein levels of APP were evaluated by quantitative Western 
blot and not different between APPtg mice with and without deletion of p38α-MAPK (F and G; t test; n ≥ 8 per group). Deletion of p38α-MAPK in 
neurons significantly reduced BACE1 protein in the brain of 9-month-old APPtg mice (H and I; t test; n ≥ 5 per group)
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measured with β-actin as an internal control, or by 25% 
with APP as an internal control (t test, P < .05). Moreover, 
we observed that APP proteins did not differ between 
APPtgp38αfl/flCre+/− and APPtgp38αfl/flCre−/− mice (F and 
G; t test, P >  .05); and BACE1 protein was significantly 
reduced in APPtgp38αfl/flCre+/− mice (Figure  3H,I; t test 
P =  .002). Thus, the marked reduction of C99 fragments 
and Aβ oligomers in the brain corroborated our recent find-
ings that p38α-MAPK deficiency inhibits the protein level 
and the activity of BACE1 in neurons and decreases cere-
bral Aβ load.13
Microglial inflammatory activation as another important 
pathogenic mechanism in AD3 had been analyzed with our 
established protocols.30 We observed that deletion of p38α-
MAPK significantly reduced the number of Iba1-positive 
cells (Figure S2A,B; t test, P < .05), downregulated the tran-
scription of pro-inflammatory genes (tnf-α, il-1β, and inos) 
and upregulated transcription of anti-inflammatory genes (il-
10 and mrc1) in the brain of APPtg mice but not in APPwt 
mice (Figure S2C-J; one-way ANOVA followed by post hoc 
test, P <  .05). Deletion of neuronal p38α-MAPK in APPtg 
mice also led to significantly upregulated transcription of 
bdnf and igf-1 in the brain, both of which encode inflamma-
tion-related growth factors and promote neuronal protection 
and regeneration (Figure S2K,L; one-way ANOVA followed 
by post hoc test, P < .05). The transcription of other tested 
genes, including ccl-2, arg1, and chi3l3, in APPtg mouse 
brains was not changed by neuronal deficiency of p38α-
MAPK (Figure S2E,H,J; one-way ANOVA followed by post 
hoc test, P > .05).
3.4 | Deletion of neuronal p38α-MAPK 
alters gene expression profile in APP-
transgenic mice
After observing that deletion of neuronal p38α-MAPK im-
proved cognitive function in APPtg mice, we performed 
transcriptome analysis to identify potential mechanisms 
that mediate neuronal protection. Next-generation sequenc-
ing of mRNA isolated from cortex and hippocampus of 
APPtgp38αfl/flCre+/− and APPtgp38αfl/flCre−/− littermate mice 
resulted in 36  437 sequenced transcript identifications for 
15  011 individual genes with different transcript variants. 
Among identified gene transcripts, 253 gene transcripts were 
altered by log2 fold change <−2 or >2 and with a FDR cor-
rected P < .01. From these altered gene transcripts 107 were 
downregulated and 146 were upregulated in APPtgp38αfl/
flCre+/− mice as compared with APPtgp38αfl/flCre−/− litter-
mate controls (see Figure  4A,B). All significantly altered 
transcripts, also with P value of <.05, are shown by their 
gene name and with their corresponding log FC and FDR 
values in Table S1.
By applying the Kyoto Encyclopedia of Genes and 
Genomes pathway analysis tool of the Pathview annotation 
software, we performed pathway enrichment analysis of all 
253 significantly altered gene transcripts. Pathways such as 
MAPK signaling, spliceosome formation and calcium sig-
naling were found to be enriched for genes differentially 
regulated by neuronal deletion of p38α-MAPK. Heat maps 
showed the differences in transcript variants of gene expres-
sion (Figure 4C-E). As expected, the MAPK signaling path-
way was altered in p38α-MAPK-deficient mouse brain. In 
this pathway, the gene transcription of mapk9, also known 
as C-Jun N-terminal kinase (jnk2) was strongly upregulated 
in p38α-MAPK-deficient mouse brain, which might indicate 
a compensatory mechanism. JNK2 acts in a parallel MAPK 
signaling cascade and shares some common substrates with 
p38α-MAPK. Interestingly, the transcription of genes asso-
ciated with the spliceosome was significantly modified by 
deletion of neuronal p38α-MAPK, which might represent an 
important mechanism through which p38α-MAPK regulates 
gene transcription, as the spliceosome removes introns from a 
transcribed precursor messenger RNA (pre-mRNA).41 Indeed 
disturbance in spliceosome function with reduced maturation 
of pre-mRNA has been reported in Aβ-challenged neuronal 
cells.42 In addition to these genes that were included into the 
enrichment analysis (see Figure 4E), there were 11 calcium 
signaling-related genes (adarb1, ano4, dtnb, map2, nfatc2, 
plch1, s100a5, sox5, tec, tfap2b, and tmem63c), whose tran-
scription was also significantly changed by deletion of p38α-
MAPK in neurons (see Table S1). Using the online database, 
PanglaoDB (https://pangl aodb.se/), we analyzed the cellular 
origin of transcriptionally altered genes. We observed that 
these spliceosome pathway and calcium signaling-related 
genes whose transcription was changed by p38α-MAPK de-
ficiency were enriched in neuronal populations instead of in 
microglia and other glial cells.43
To validate the results derived from sequencing experi-
ments, we performed quantitative RT-PCR to measure tran-
scripts of the following genes, which are involved in calcium 
signaling and/or synaptic plasticity: adcy3, adcy7, atp2b4, 
gnas, grin2a, htr7, slc8a1, sphk1, tmem63c, plch1, and 
nfatc2. As shown in Figure 5, the alteration of gene transcrip-
tion screened by next-generation sequencing could be con-
firmed by PCR (t test, P < .05).
3.5 | Deletion of neuronal p38α-MAPK 
differently regulates glutamate and NMDA-
induced calcium influx and cell death in 
primary cultured neurons
After observing that p38α-MAPK deficiency altered the 
transcription of calcium homeostasis-related genes in 
brain tissues, we asked whether p38α-MAPK regulates 
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the calcium influx in neurons. We cultured p38α-deficient 
and wild-type cortical neurons from the breeding between 
APPtgp38fl/flNex-Cre+/− (or APPwtp38fl/flNex-Cre+/−) 
male mice and APPwtp38fl/flNex-Cre−/− female mice. We 
first validated the neuronal reduction of p38α-MAPK by 
quantitative Western blot. The p38α-MAPK-deficient 
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neurons (APPtgp38fl/flNex-Cre+/−) showed a reduced pro-
tein level of p38-MAPK by nearly 80% compared to the 
wild-type neurons (APPtgp38fl/flNex-Cre−/−) (Figure  6A; 
t test, P =  .026). Interestingly, we observed that the pro-
tein level of Grin2a, a subunit of NMDAR, was lower in 
p38α-MAPK-deficient neurons than in wild-type cells 
(Figure 6B; t test, P = .010).
Then, we examined effects of APP/PS1-overexpression 
on calcium influx. We challenged APPtgp38fl/flNex-Cre−/− 
and APPwtp38fl/flNex-Cre−/− neurons with l-glutamate (at 
100 and 500 µM) or NMDA (at 50 µM and 10mM) followed 
by 75 mM KCl. The calcium influx was not different between 
these two groups of neurons (Figure S3A,B; n ≥ 3 animals 
per group). In the culture medium of APP/PS1-transgenic 
neurons, we could not detect Aβ with Western blot (data not 
shown). The concentration of Aβ in calcium imaging cham-
ber should be even lower after cells were further perfused 
with Aβ-free imaging buffer. We supposed that Aβ at such 
a low level was not able to trigger calcium influx as previ-
ously reported.44 Moreover, overexpression of PS1 appeared 
not to alter glutamate receptors-mediated calcium influx in 
our cultured neurons, although mutant PS1 potentially reg-
ulates calcium release from endoplasmic reticulum and af-
fect store-operated calcium channels.45 Thus, we used both 
APP-transgenic (APPtg) and wild-type (APPwt) neurons for 
the following experiments.
F I G U R E  4  Deletion of p38α-MAPK in neurons changes cerebral gene expression in APP-transgenic mice. A, Next generation sequencing 
of mRNA libraries prepared from 9-month-old neuronal p38α-MAPK-deficient (ko; n = 5) and wild-type (wt; n = 4) APP-transgenic mouse brains 
identified 36 437 transcripts and 15 011 individual genes. Among these gene transcripts, 253 were altered (107 downregulated and 140 upregulated) 
by p38α-MAPK deficiency with log2-folded changes <−2 or >2 and corrected P values of FDR < 0.01. B, Volcano plot shows the fold changes of 
gene transcripts (log2 scale) in p38α-MAPK ko mouse brain compared to wt mouse brains (x-axis) and relevant significance (y-axis, log10 scale). 
Downregulation is marked in green and upregulation in red. C-E, Heat maps reveal differently expressed transcript variants of genes. Each gene 
has different transcript variants, the significantly altered ones are indicated with the star of significance. Data are expressed as mean fragments 
per kilobase of transcript per million reads (FPKM), standardized, and visualized using the MATLAB clustergram script. Red, relatively high 
expression; blue, relatively low expression in p38α-MAPK ko mice; ** for FDR < 0.01 and *** for FDR < 0.001
F I G U R E  5  Deletion of p38α-MAPK alters transcription of calcium signaling and synaptic plasticity-related genes in APP-transgenic mouse 
brain. Nine-month-old APP-transgenic mice with (ko) and without (wt) deletion of neuronal p38α-MAPK were analyzed for transcriptions of 
calcium signaling and synaptic plasticity-related genes. Total RNA was isolated from the brain and reverse transcribed. Real-time PCR was used to 
detect gene transcripts (t test; n ≥ 7 per group)
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We treated APPwtp38fl/flNex-Cre+/− and APPwtp38fl/
flNex-Cre−/− neurons with 75  mM KCl to induce mem-
brane depolarization. Substantial calcium influx was clearly 
induced in both neurons and the responses were higher in 
p38α-MAPK-deficient neurons than in p38α-MAPK-wild-
type cells (Figure 6C; two-way ANOVA, P <  .001). When 
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cells were activated with 100 µM and 500 µM l-glutamate, de-
letion of p38α-MAPK significantly enhanced calcium influx 
as compared with p38α-MAPK-wild-type cells (Figure 6D; 
two-way ANOVA, P <  .001). The calcium influx could be 
further induced by adding 75 mM KCl after glutamate treat-
ments. Similarly, we treated neurons with NMDAR-specific 
agonist, NMDA. Interestingly, p38α-MAPK-deficient neu-
rons showed little calcium influx (F/F0 from 0.990 to 1.159) 
even after application of 10  mM NMDA, whereas, p38α-
MAPK-wild-type neurons demonstrated pronounced calcium 
influx after treatment with 50 µM NMDA (F/F0 from 1.00 
to 1.286) (Figure  6E; two-way ANOVA, P  <  .001). After 
NMDA treatments, p38α-MAPK-deficient and wild-type 
cells were further stimulated with 75 mM KCl and displayed 
a comparable increase of calcium signals, which indicated 
that the mild elevation of calcium signal in p38α-MAPK-de-
ficient neurons was not due to the neurotoxicity of NMDA.
We also treated APPtgp38fl/flNex-Cre+/− and APPtgp38fl/
flNex-Cre−/− neurons with 100  µM l-glutamate. The peak 
level of calcium influx in p38α-MAPK-deficient neurons was 
significantly higher than in p38α-MAPK-wild-type neurons 
(Figure 6F; F/F0: 1.67 ± 0.04 vs 1.52 ± 0.04 in APPtgp38fl/
flNex-Cre+/− and APPtgp38fl/flNex-Cre−/− neurons, respec-
tively; t test, P = .037). Interestingly, when l-glutamate was 
washed out, the intensity of calcium-associated Fluo-4 flu-
orescence dropped significantly faster in p38α-MAPK-de-
ficient neurons than in p38α-MAPK-wild-type neurons 
(Figure  6F; two-way ANOVA, P  <  .001). The decay time 
for calcium fluorescence was 32.00  ±  5.34  seconds vs 
123.00  ±  26.47  seconds in APPtgp38fl/flNex-Cre+/− and 
APPtgp38fl/flNex-Cre−/− neurons, respectively (Figure 6G; t 
test, P = .013).
To investigate how p38α-MAPK deficiency enhanced 
calcium influx, we continued to co-treat APPtgp38fl/fl-
Nex-Cre+/− and APPtgp38fl/flNex-Cre−/− neurons from 
the wash-out experiment with 100 µM l-glutamate and a 
NMDAR antagonist, APV-2. Calcium flux was again in-
duced although the intra-neuronal levels of calcium were 
lower than in cells treated with glutamate alone (Figure 6F). 
The peak level of calcium influx in p38α-MAPK-deficient 
neurons was still higher than that in p38α-MAPK-wild-
type neurons (Figure 6F; F/F0: 1.34 ± 0.03 vs 1.09 ± 0.03 
in APPtgp38fl/flNex-Cre+/− and APPtgp38fl/flNex-Cre−/− 
cells, respectively; t test, P  =  .001). When p38α-MAPK 
deficiency-associated enhancement of calcium influx was 
compared in neurons that were challenged with l-gluta-
mate in presence and absence of APV-2, we observed that 
blocking NMDAR potentially amplified the effect of p38α-
MAPK deficiency on calcium influx. When peak levels of 
calcium influx in p38α-MAPK-wild-type neurons were set 
at 100% in both experimental settings, p38α-MAPK dele-
tion elevated maximal calcium influx to 122.93 ± 3.11% 
in the presence of APV-2 and to 109.99  ±  2.61% in the 
absence of APV-2 (Figure 6F,H; t test, P = .019).
In the end, we analyzed the neurotoxic effects of cal-
cium influx upon challenges of l-glutamate and NMDA. 
Deletion of p38α-MAPK significantly inhibited activation 
of caspase-3 in cultured neurons after treatments with both 
l-glutamate at 100 µM (Figure 7A) and NMDA at 50 µM 
(Figure  7B) (t test between p38α-MAPK deficient and 
wild-type neurons, P = .032 for l-glutamate and 0.039 for 
NMDA).
3.6 | Deletion of p38α-MAPK in neurons 
attenuates cognitive deficits and synaptic 
impairments in Tau-transgenic mice
APPtg mice cannot model all pathological changes of AD, 
such as those associated with p-Tau. To investigate the 
effects of neuronal p38α-MAPK on the Tau-associated 
pathological changes in AD, we cross-bred p38αfl/fl mice,25 
Nex-Cre mice,26 and P301S Tau-transgenic (Tautg) mice27 
to create neuronal p38α-MAPK-deficient Tautg AD mice. 
The lower level of p38-MAPK protein in the brain ho-
mogenate derived from Tautgp38αfl/flCre+/− mice com-
pared to Tautgp38αfl/flCre−/− mice confirmed the deletion 
of p38α-MAPK (Figure  8A; t test, P  <  .001). We also 
measured p38-MAPK activities in brains of 9-month-
old Tautgp38αfl/flCre+/− and Tautgp38αfl/flCre−/− mice, 
F I G U R E  6  Deletion of p38α-MAPK reduces Grin2a proteins and regulates calcium influx in primary neurons. Primary neurons were 
cultured from neuronal p38α-MAPK deficient (ko) and wild-type (wt) embryos. Western blot detected lower protein levels of p38-MAPK and 
NMDAR subunit Grin2a (A and B; t test, n ≥ 5 per group). Fluo-4 fluorescent intensity (F) in neurons was measured before and after stimulation 
with: i) 75 mM KCl alone (C), ii) 100 µm, 500 µM l-glutamate (Glu) and 75 mM KCl (D), and iii) 50 µM, 10 mM NMDA and 75 mM KCl (E). 
F0 was record at 0 second. Deletion of p38α-MAPK enhanced KCl or Glu-triggered but inhibited NMDA-initiated calcium influx (C-E; two-way 
ANOVA showing difference between p38α-MAPK ko and wt cells; n ≥ 7 per group. For each group, more than 481 neurons were analyzed). 
As shown in (F), p38α-MAPK-ko and wt neurons were also serially treated with: i) 100 µM l-Glu for 20 s, ii) washing out for 160 s, iii) 100 µM 
NMDAR antagonist, APV-2, for 300 s, and iv) 100 µM l-Glu together with APV-2 for 20 s. During wash-out phase, the intensity of Fluo-4 
fluorescence dropped down much faster in p38α-MAPK-ko cells than in wt neurons (two-way ANOVA showing effects of genotypes; n ≥ 4 per 
group, in which total 26 ko neurons and 112 wt neurons were analyzed). The decay time for the Fluo-4 fluorescence was significantly shorter 
in p38α-MAPK-ko cells than in wt neurons (G; t test, n ≥ 4 per group). The increase (Δ) of Glu-induced peak F/F0 in p38α-MAPK-ko neurons 
compared with that in p38α-MAPK-wt neurons (set at 100%) was calculated. Interestingly, Δ(F/F0) was significantly higher during Glu treatment 
in the presence of APV-2 than during the treatment with Glu alone (H; t test, n ≥ 4 per group)
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and their non-Tau-transgenic (Tauwt) littermate controls 
(Tauwtp38αfl/flCre+/− and Tauwtp38αfl/flCre−/−). The phos-
phorylation of p38-MAPK was increased in the brain of 
Tautg mice compared to Tauwt mice. Deletion of p38α-
MAPK inhibited the phosphorylation of p38α-MAPK in 
Tautg mouse brain but not in Tauwt brain (Figure  8C,D; 
one-way ANOVA, P < .05).
We have recently observed that the cognitive function 
of Tautg mice is impaired in the Morris water maze test.28 
Compared to Tautgp38αfl/flCre−/− littermates, 9-month-
old Tautgp38αfl/flCre+/− mice traveled in significantly less 
time and over less distance to reach the escaping platform 
in the training phase, but the swimming velocity did not 
differ between these two groups of mice (Figure  8E-G; 
two-way ANOVA, P <  .05). Similarly, in the probe trial, 
Tautgp38αfl/flCre+/− mice found the original region for plat-
form within a shorter time, crossed the target position more 
frequently and explored in the target region for longer du-
ration than Tautgp38αfl/flCre−/− littermates (Figure 8H-J; t 
test, P < .05).
Levels of the synaptic structure proteins Munc18-1, 
PSD-95, and synaptophysin are reduced in the brains of 
Tautg mice compared to wild-type (Tauwt) controls.28 
Interestingly, the protein levels of Munc18-1 and synapto-
physin in brain homogenates of 9-month-old Tautgp38αfl/
flCre+/− mice were significantly elevated by the deletion of 
p38α-MAPK in neurons compared to Tautgp38αfl/flCre−/− 
mice (Figure 8K,M; t test, P < .05). Deletion of neuronal 
p38α-MAPK in Tautg mice tended to restore the cerebral 
protein level of PSD-95, but the change was not significant 
(Figure 8N; t test, P = .05).
3.7 | Deletion of p38α-MAPK in neurons 
reduces cerebral p-Tau protein in Tau-
transgenic mice
As p-Tau mediates toxic effects of Aβ in AD pathogenesis,46,47 
we investigated effects of neuronal deficiency of p38α-
MAPK on cerebral p-Tau levels. We counted AT8-positive 
cells in cortex and hippocampus of 9-month-old Tautgp38αfl/
flCre−/− and Tautgp38αfl/flCre+/− mice. The total number of 
AT8-immunoreactive cells adjusted to the investigated area 
in Tautgp38αfl/flCre−/− mice (16.51 ± 1.94/mm2 in cortex and 
35.40 ± 4.75/mm2 in hippocampus) was significantly higher 
than that in Tautgp38αfl/flCre+/− mice (7.50  ±  2.53/mm2 in 
cortex, and 18.71 ± 4.34/mm2 in hippocampus; Figure 9A,B; 
t test for Tautgp38αfl/flCre+/− vs Tautgp38αfl/flCre−/− mice, 
P  =  .013 and 0.021, respectively). We also stained brain 
tissues with thioflavine S to identify neurofibrillary tangles 
using a published method.31 We observed very few thiofla-
vine staining-positive cells in the whole brain (Figure 9C). 
However, deletion of p38α-MAPK did reduce the number 
of staining-positive cells in both cortex and hippocampus 
(Figure 9D; t test, P = .039 and 0.039, respectively).
We extracted Tau proteins from 9-month-old Tautgp38αfl/
flCre+/− and Tautgp38αfl/flCre−/− mice with RAB, RIPA, 
and FA buffers. Western blots revealed that both the protein 
levels of p-Tau seen with direct densitometry and ratios of 
p-Tau/t-Tau were significantly lower in RIPA and FA frac-
tions derived from Tautgp38αfl/flCre+/− mice, compared to 
Tautgp38αfl/flCre−/− mice (Figure 9F,G; t test, P < .05). In the 
RAB fraction, deletion of neuronal p38α-MAPK tended to 
decrease the cerebral p-Tau level in Tautg mice, although the 
difference was not significant (Figure 9E; t test, P > .05). In 
all three fractions of brain homogenate, Tautgp38αfl/flCre+/− 
and Tautgp38αfl/flCre−/− littermate mice did not differ in t-Tau 
protein levels (data not shown).
We have recently observed that activated autophagy is 
able to degrade p-Tau in the tau-transgenic mouse brain.28 We 
further detected autophagy markers, LC3B-I and LC3B-II, 
in RIPA-soluble brain homogenate. As shown in Figure 9H, 
the ratio of LC3B-II/I was significantly higher in Tautgp38αfl/
flCre+/− mouse brain than that in Tautgp38αfl/flCre−/− mice (t 
test, P < .05).
4 |  DISCUSSION
Aβ and p-Tau are two major pathogenic molecules in 
AD. In our study, we demonstrated that deletion of neu-
ronal p38α-MAPK improves cognitive function of both 
9-month-old APP and tau-transgenic AD mice, which is 
associated with reduced Aβ and p-Tau load, and shifting 
from pro- to anti-inflammatory activation in the brain. We 
F I G U R E  7  Deletion of p38α-MAPK attenuates both l-glutamate 
and NMDA-induced apoptosis in primary neurons. Primary neurons 
were cultured from APP-transgenic embryos with (ko) and without 
(wt) deletion of p38α-MAPK in neurons. Western blot detected 
significant reduction of cleaved caspase-3 (Casp-3) in p38α-MAPK-
ko cells compared with p38α-MAPK-wt controls after treatments 
with 100 μM l-glutamate (Glu) (A; t test; n ≥ 4 per group) and 50 μM 
NMDA (B; t test; n ≥ 4 per group) for 16 h
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F I G U R E  8  Deletion of p38α-MAPK in neurons improves cognitive function and attenuates synaptic impairments in Tau-transgenic mice. 
The deletion of p38α-MAPK in Tau-transgenic (tg) mice was confirmed by detecting p38-MAPK in the brain homogenate with quantitative 
Western blot (A and B; t test; n ≥ 8 per group). The homogenates of brain derived from 9-month-old Tautg and non-Tau-transgenic (wt) littermate 
mice with (ko) without (wt) deletion of p38α-MAPK were analyzed for phosphorylated (p-p38) and total (t-p38) p38-MAPK with Western blot. 
In this experiment, the loading protein for each lane was adapted to have similar amount of t-p38. The protein level of p-p38 in Tautg mice with 
normal expression of p38α-MAPK was higher than in Tauwt littermates. Deletion of p38α-MAPK reduced phosphorylation of p38-MAPK in 
Tautg mice but not in Tauwt mice (C and D, one-way ANOVA followed by Bonferroni post hoc test, n ≥ 4 per group). Morris water maze was 
performed to evaluate the cognitive function of 9-month-old Tautg mice with and without deletion of p38α-MAPK in neurons. During the training 
phase, p38α-MAPK wt mice spent significantly more time and traveled longer distances to reach the hidden platform than did their p38α-MAPK 
ko littermates. The swimming speed was not different between both genotypes (E-G; two-way ANOVA showing the effect of genotype; n ≥ 8 
per group). In the probe trial, Tautg p38α-MAPK ko mice spent significantly shorter time in the first visit of the region where the platform was 
previously located, crossed the platform region with significantly more frequency and spent significantly longer time in the platform region during 
the total 5-minute experiment than their Tautg p38α-MAPK wt littermates (H-J; t test; n ≥ 8 per group). After water maze, the brain was collected 
for further biochemical analysis. The amount of synaptic structure proteins, such as Munc18-1, SNAP25, synaptophysin (SYN), and PSD95, was 
quantified with Western blot (K-N). Neuronal deficiency of p38α-MAPK was associated with a higher level of Munc18-1, synaptophysin and 
PSD95 in Tautg mice (K, M and N; t test; n ≥ 5 per group)
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F I G U R E  9  Deletion of p38α-MAPK in neurons reduces p-Tau load in Tau-transgenic mice. Nine-month-old Tau-transgenic (tg) littermate 
mice with (ko) and without (wt) deletion of neuronal p38α-MAPK were analyzed for cerebral p-Tau load after immunofluorescent labeling with 
AT8 antibody (A) as well as for neurofibrillary tangles with thioflavine S (ThioS) staining (C). The p-Tau- or ThioS staining-positive cells were 
counted and adjusted by the relevant brain area. Deletion of p38α-MAPK in neurons significantly reduced the cerebral p-Tau-positive (B; t test; 
n = 8 per group) and ThioS staining-positive cells (D; t test; n ≥ 5 per group). Tau proteins were extracted from 9-month-old Tautg mice with RAB, 
RIPA, and FA buffers and detected with Western blots for both phosphorylated and total Tau (p-Tau and t-Tau, respectively) (E-G). The protein 
levels of p-Tau are presented as both density (in arbitrary unit [AU]) and the ratio of p-/t-Tau. Deficiency of p38α-MAPK in neurons significantly 
reduces p-Tau proteins in RIPA and FA fractions, but not in RAB fraction (F and G; t test; n ≥ 4 per group). The RIPA fraction was further used to 
detect the autophagy marker LC3B-I and LC3B-II. Deletion of p38α-MAPK increased the ratio of LC3B-II/I (H; t test; n ≥ 6 per group)
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further showed that p38α-MAPK regulates calcium home-
ostasis. Especially the NMDA receptor-mediated calcium 
influx in neurons was affected, which might regulate neu-
ronal plasticity and death in AD and in other neurodegen-
erative diseases.
Our previous study has shown that inhibition of p38α-
MAPK enhances autophagy in neurons, which promotes ly-
sosomal degradation of BACE1.13 As APP and C-terminal 
fragment of APP (C99) are also substrates of autophagy,48 
it is likely that p38α-MAPK inhibition reduces Aβ genera-
tion. Although we have not investigated p38α-MAPK-de-
ficient microglia, other studies have shown that inhibition 
of p38α-MAPK potentially activates autophagy in macro-
phages.49 Since autophagy both promotes the recycling of 
Aβ-phagocytosing receptors CD36 and TREM250 and facil-
itates Aβ degradation in microglia,51 perhaps treatment with 
p38α-MAPK inhibitor has the potential to degrade Aβ in AD 
patients. We observed that deletion of neuronal p38α-MAPK 
inhibits pro-inflammatory, but enhances anti-inflammatory 
activation in the brain of APP-transgenic mice. The inflam-
matory changes are likely secondary to the cerebral Aβ re-
duction; however, provide a further protection for neurons.3 
Moreover, autophagy is an efficient mechanism to degrade 
p-Tau in the brain,28,52 inhibition of p38α-MAPK not only 
inhibits Tau phosphorylation15,53 but should also increase 
p-Tau clearance in the AD brain. In Tau-transgenic mouse 
brain, we for the first time showed that deletion of p38α-
MAPK in neurons attenuates p-Tau protein. It was correlated 
with enhancement of autophagy. However, as t-Tau protein 
levels in the brain are not affected by neuronal p38α-MAPK 
deficiency, the decrease of cerebral p-Tau is more likely due 
to the reduced phosphorylation of Tau proteins.
Furthermore, our study shows that phosphorylation of p38-
MAPK is only increased in the brain but not in heart, liver and 
muscles in APP-transgenic mice, which corroborates the obser-
vation that p38-MAPK is locally activated at AD lesion sites 
in human brains.11,12 Our careful evaluation indicates that de-
ficiency of neuronal p38α-MAPK does not affect the survival 
and cognitive function of APP-wild-type mice. Thus, inhibition 
of p38α-MAPK might serve preventive and therapeutic effects 
against AD progress by targeting several key pathogenic mech-
anisms and limit its potential off-target actions.
Apart from its effects on autophagy, we observed that 
p38α-MAPK regulates transcription of many calcium ho-
meostasis-related genes in APP-transgenic mouse brain. 
Especially transcription and protein levels of NMDAR sub-
unit NR2A (encoded by grin2a gene) are both downregulated 
in p38α-deficient mouse brains. NMDAR mediates effects 
of the primary excitatory neurotransmitter glutamate. Under 
physiological condition, activation of NMDAR is essential 
for neuronal plasticity or long-term potentiation (LTP); how-
ever, under pathological conditions, such as in AD, NMDAR 
might increase calcium influx, which leads to excitotoxicity.54 
Aβ oligomers were reported to directly activate NMDARs, 
particularly NR2A-contained receptors.55 Aβ oligomers also 
block re-uptake of released glutamate from astrocytes and 
neurons, which leads to perisynaptic glutamate accumula-
tion.56 In APP-transgenic mouse brain, the level of resting 
calcium increases in neurites surrounding Aβ deposits.57 
Aβ oligomers-induced calcium overload in dendritic spines 
can be prevented by blocking NMDAR.44 Memantine, as a 
NMDAR antagonist, has been proved to improve cognitive 
function and daily living of AD patients.58 In our cultured 
neurons, deletion of p38α-MAPK suppresses NMDA-
induced calcium influx and neuronal apoptosis, which sup-
ports that inhibition of p38α-MAPK protects neurons against 
calcium overload-induced neurotoxicity in AD.
Deletion of p38α-MAPK also controls the neuronal ex-
citotoxicity by regulating calcium buffering. In this study, 
we observed that p38α-MAPK deficiency increased the 
gene expression of sodium/calcium exchanger 1 (Slc8a1) in 
APPtg mouse brain. Slc8a1 is located at plasma membranes, 
mitochondria, and endoplasmic reticulum (ER) of excitable 
cells, pumping cytoplasmic calcium out of cells or into cal-
cium storage organelles.59 Moreover, we detected reduced 
gene expression of sigma non-opioid intracellular receptor 1 
(Sigmar1) in p38α-MAPK-deficient mice. Sigmar1 resides at 
mitochondria-associated ER membrane, inhibiting store-op-
erated calcium entry.60 Inhibition of Sigmar1 was reported 
to attenuate cognitive deficits in an AD mouse model with 
intraventricle Aβ injection.61 In our cultured neurons, de-
letion of p38α-MAPK enhances both glutamate-triggered 
calcium influx and the clearance of cytoplasmic calcium 
after glutamate removal. The rapid calcium clearance might 
compensate for the neurotoxic effects of elevated calcium 
level in p38α-MAPK-deficient neurons. Thus, inhibition of 
p38α-MAPK potentially protects neurons in AD brain by en-
hancing intracellular clearance of calcium, although the un-
derlying mechanisms need to be further identified.
It should be noted that deletion of p38α-MAPK in-
creased l-glutamate-induced calcium influx, but decreased 
cytoplasmic calcium when cells were activated by NMDA. 
The increase of glutamate-induced calcium influx in 
p38α-MAPK-deficient neurons is obviously mediated by 
non-NMDARs glutamate receptors, such as AMPA receptor, 
kainate receptors, and metabotropic-type glutamate receptors 
(mGluRs). In group 1 mGluRs activation-induced long-term 
depression (LTD), p38-MAPK activation initiates internal-
ization of AMPA receptors at synapses.62 Thus, p38α-MAPK 
deficiency has the potential to preserve more AMPA receptors 
on the cell surface to facilitate the calcium entry. It is import-
ant to evaluate this possibility not only in cultured neurons 
but also in AD brain, as AMPA receptor-mediated calcium 
influx leads to synaptic dysfunction and neurodegeneration.63
Excitatory synapses contain AMPA and NMDA recep-
tors, and mGluRs on dendritic spines. AMPA receptors 
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mediate most neuronal basal transmission. Aβ treatments 
share the mechanisms with LTD to drive the endocytosis 
of synaptic AMPA receptors, which results in synaptic de-
pression and dendritic spine loss.18 Inhibition of neuronal 
p38α-MAPK has the potential to inhibit Aβ-induced LTD 
by blocking internalization of AMPA receptors.62 Soluble 
Aβ also impairs LTP by increasing the activity of extra-
synaptic NMDARs. Inhibition of p38-MAPK has been 
observed to abolish Aβ-caused inhibition of LTP in hip-
pocampal slices.17 We did not analyze electrophysiological 
activity of neurons in our AD mice; however, we observed 
that deficiency of neuronal p38α-MAPK improves the cog-
nitive function of APP-transgenic mice and prevents the 
loss of synaptic proteins. The preservation of maturated 
mushroom spines that are enriched with AMPA recep-
tors29 further suggests protective effects of p38α-MAPK 
deficiency on AMPA-mediated neuronal transmission in 
APP-transgenic mice. Moreover, our transcriptome analy-
sis shows that the transcription of gria1, which encodes 
AMPA receptor subunit 1, is upregulated in the brain of 
neuronal p38α-MAPK-deficient APP-transgenic mice (see 
Table S1). Thus, inhibition of neuronal p38-MAPK poten-
tially improves synaptic plasticity in AD brain.
Our study shows that p38α-MAPK deficiency protects 
neuron in AD pathogenesis. However, physiological func-
tions of p38-MAPK still need to be noted; for example, 
p38α-MAPK is essential in erythropoiesis.64 In our AD mice, 
neuronal p38α-MAPK was deleted from the birth. Our results 
indicate more preventive than therapeutic effects of p38α-
MAPK inhibition in AD.
In the last decades, many clinical interventions, especially 
Aβ immunization,65 have been attempted to reduce cerebral 
Aβ. Unfortunately, none of them resulted in efficacious thera-
pies for AD patients. Our study demonstrated that deficiency 
of neuronal p38α-MAPK ameliorates AD-associated brain 
pathology in both APP and Tau-transgenic animal mod-
els. As potential mechanisms, inhibition of neuronal p38α-
MAPK not only reduces generation of Aβ and p-Tau, but also 
protects neurons by preventing calcium overload. Our studies 
support p38α-MAPK as a novel target for AD therapy, al-
though further studies are required.
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